|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||120.13 - 123.26|
|52 Week Range||103.25 - 136.84|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||1.38|
|Expense Ratio (net)||0.35%|
The VanEck Vectors Biotech ETF (BBH) is up nearly 8% year-to-date, but some industry observers are speculating that for large-cap biotechnology stocks to rally again, some more mergers and acquisitions activity will be required. BBH holds 25 stocks and tracks the MVIS US Listed Biotech 25 Index, “which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment,” according to VanEck. Some well-known biotechnology companies are trailing the broader market this year as the healthcare sector itself is disappointing investors.
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
Biotech ETFs allow investors to buy into a basket of biotech stocks, rather than trying to select specific winners. The best biotech ETFs are diverse, with less volatility.
The news has put the spotlight on a number of healthcare ETFs, especially biotech and pharma, which could be the best ways for investors to tap the opportunity arising from the BMY-CELG deal.
VanEck announced today preliminary yearend distribution estimates for its VanEck Vectors® equity exchange-traded funds.
Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion, compared to estimates for EPS of $4.03 on revenues of $3.88 billion during the third quarter of 2018.
There are 11 analysts tracking Shire stock as of October 30. Four of them are recommending a “strong buy,” five are recommending a “buy,” and two are recommending a “hold.” None of them have recommended a “sell.” The changes in analysts’ estimates and recommendations are based on changing trends in the stock and the company’s performance.
Wall Street analysts estimate Incyte’s (INCY) revenues will increase by ~17.7% to $449.2 million during the third quarter of 2018 compared to revenues of $381.5 million during the third quarter of 2017. Also, the earnings per share are estimated to be $0.40 for the third quarter of 2018 as compared to earnings per share of $0.08 for the third quarter of 2017. Incyte stock has fallen nearly 46.6% over the last 12 months and decreased by ~35.7% in 2018 year-to-date.
As we discussed earlier, analysts expect Amgen (AMGN) to report nearly flat revenues at $5.77 billion during the third quarter. Amgen’s product portfolio includes human therapeutics.
Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decrease 3.8% to $3.88 billion. Allergan has classified its business operations into three business segments: US Specialized Therapeutics US General Medicine International
Wall Street analysts expect Biogen’s (BIIB) third-quarter revenues to increase ~8.2% to $3.33 billion—compared to its revenues of $3.07 million during the third quarter of 2017. Biogen’s stock price has decreased nearly 4.1% in the last 12 months. Analysts’ recommendations show a 12-month target price of $390.88 per share—compared to the last price of $330.15 per share as of October 18.
ESPO provides targeted exposure to “the future of sports”: video game and related software developers, streaming services, companies involved in eSports events, and more
Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.
Allergan’s (AGN) product portfolio includes generic pharmaceutical products and specialty pharmaceutical products. The company’s business comprises three segments—US General Medicines, US Specialized Therapeutics, and International. The chart below compares Allergan’s revenues and EPS since the first quarter of 2017, as well as its estimates for the third quarter.
Ionis Pharmaceuticals (IONS) develops drugs for life-threatening diseases, and it commercializes the approved products in collaboration with other pharmaceutical companies. Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in YoY (year-over-year) revenues compared to the second quarter of 2017.
Allergan (AGN) is a specialty pharmaceutical company focused on organic as well as inorganic growth methods. The chart below highlights several recent developments for Allergan.
Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017. Analysts expect Shire’s net adjusted income to increase to $4.68 billion in 2018 compared to its net adjusted income of $4.60 billion in 2017. Shire’s stock price has risen nearly 15.4% in the last 12 months, and it’s risen ~15.7% year-to-date in 2018.
Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.
Incyte (INCY), a biopharmaceutical company, is focused on the discovery, development, and commercialization of various products to cater to unmet medical needs in oncology and the treatment of other diseases.
As we discussed earlier, Amgen (AMGN) reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017. Amgen surpassed analysts’ estimates for EPS and revenue in the second quarter, reporting non-GAAP (generally accepted accounting principles) EPS of $3.83 on revenue of ~$6.1 billion compared to the estimate of $3.54 on revenue of $5.7 billion.